Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Guidelines recommend routine urine albumin-to-creatinine ratio (uACR) screening in patients with diabetes (annual) and hypertension (at least once, with follow-up annually if CKD is found). However, real-world adherence remains uncertain and appears suboptimal. This study aimed to quantify the global prevalence of albuminuria testing in high-risk adults with hypertension and/or diabetes.
We conducted a systematic review and meta-analysis of observational studies reporting the proportion of adults with diabetes mellitus, hypertension, or both who underwent albuminuria screening in routine care. Multiple databases were searched through Web of Science, PubMed, Google Scholar, and Scopus. Pooled testing prevalence was calculated using random-effects meta-analysis of proportions, with heterogeneity assessed by Cochran’s Q and I² statistics. Subgroup analyses examined differences by patient group, test modality, and country income level.
Thirty studies (from diverse countries and settings) met the inclusion criteria, involving over 29 million patients. Albuminuria testing rates were low in most settings. Overall, only about one in five high-risk patients underwent a uACR test in routine clinical practice. Pooled prevalence was approximately 22% (fixed-effect model dominated by a large U.S. dataset), and 49% (95% CI: 7–93%) in a random-effects model accounting for extreme between-study variability (I² ~100%). Testing uptake ranged from <5% in some systems to nearly 100% in protocolized programs. Subgroup comparisons showed higher rates in diabetes-focused and screening-driven studies, whereas hypertension cohorts had particularly low uptake.
Albuminuria screening remains underutilized among patients with hypertension or diabetes. This gap between guidelines and practice leads to delayed CKD detection and timely initiation of appropriate treatment.
